Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-307 M1AChR Occupancy PET Study
NCT04941781Phase 1Completed
- Sponsor
- Contineum Therapeutics
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PIPE-307 in multiple sclerosis (MS), sponsored by Contineum Therapeutics. Primary endpoint: M1AChR receptor occupancy at 24 hours. Started Sep 2021; status: completed.
02
Drugs
PIPE-307
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04941781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04941781.